Monte Rosa Therapeutics, Inc. Segments Disclosure
15. Segment data
The Company defines its segments based on the way in which internally reported financial information is regularly reviewed by the chief operating decision maker, or CODM, to analyze financial performance, make decisions, and allocate resources. The Company manages its operations as a single operating and reportable segment committed to developing a portfolio of novel and proprietary MGDs. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. As the internal reporting is based on the consolidated results, the Company has identified one operating and reportable segment. The CODM uses net income (loss) in the budget and forecasting process and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources. The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.
The accounting policies used in the segment reporting are the same as those described in Note 2, Summary of significant accounting policies. The Company’s CODM is the Chief Executive Officer.
The Company's reportable segment net revenues and loss for the years ended December 31, 2025 and 2024, consisted of the following:
|
|
Year ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Revenue: |
|
|
|
|
|
|
||
Collaboration revenue |
|
$ |
123,672 |
|
|
$ |
75,622 |
|
Operating expense: |
|
|
|
|
|
|
||
Research and development: |
|
|
|
|
|
|
||
External research and development expenses: |
|
|
|
|
|
|
||
MRT-2359 |
|
|
8,959 |
|
|
|
12,332 |
|
MRT-6160 |
|
|
7,539 |
|
|
|
15,209 |
|
MRT-8102 |
|
|
19,696 |
|
|
|
10,163 |
|
Other development and discovery programs |
|
|
25,198 |
|
|
|
14,432 |
|
Personnel expense |
|
|
46,241 |
|
|
|
39,796 |
|
Overhead and administrative expense |
|
|
33,867 |
|
|
|
29,631 |
|
General and administrative expenses: |
|
|
|
|
|
|
||
Personnel expense |
|
|
22,975 |
|
|
|
22,153 |
|
Professional services |
|
|
5,740 |
|
|
|
5,091 |
|
Facility costs and other expense |
|
|
7,665 |
|
|
|
7,927 |
|
Interest and other income, net |
|
|
14,485 |
|
|
|
10,982 |
|
Income tax benefit (provision) |
|
|
1,097 |
|
|
|
(2,570 |
) |
Net loss |
|
$ |
(38,626 |
) |
|
$ |
(72,700 |
) |
Other development and discovery expenses are related to the development of our QuEENTM discovery engine and our disclosed and undisclosed programs, including CDK2 and CCNE1. The Company's tangible assets are held in the U.S. and Switzerland, with 29% and 28% of the assets held in Switzerland as of December 31, 2025 and 2024, respectively. The Company's collaboration revenue is generated in the U.S. and Switzerland, with 90% and 100% of the collaboration revenue generated in Switzerland during the years ended December 31, 2025 and 2024, respectively.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 17, 2026 | Showing above |
| 2024 | Mar 20, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.